BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33547169)

  • 1. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
    Franzetti M; Forastieri A; Borsa N; Pandolfo A; Molteni C; Borghesi L; Pontiggia S; Evasi G; Guiotto L; Erba M; Pozzetti U; Ronchetti A; Valsecchi L; Castaldo G; Longoni E; Colombo D; Soncini M; Crespi S; Maggiolini S; Guzzon D; Piconi S
    J Immunol; 2021 Apr; 206(7):1569-1575. PubMed ID: 33547169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
    Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
    J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open label trial of anakinra to prevent respiratory failure in COVID-19.
    Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
    Elife; 2021 Mar; 10():. PubMed ID: 33682678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
    Della-Torre E; Lanzillotta M; Campochiaro C; Cavalli G; De Luca G; Tomelleri A; Boffini N; De Lorenzo R; Ruggeri A; Rovere-Querini P; Castagna A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; Dagna L
    Front Immunol; 2021; 12():675678. PubMed ID: 33995419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.
    Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O
    Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
    Cavalli G; De Luca G; Campochiaro C; Della-Torre E; Ripa M; Canetti D; Oltolini C; Castiglioni B; Tassan Din C; Boffini N; Tomelleri A; Farina N; Ruggeri A; Rovere-Querini P; Di Lucca G; Martinenghi S; Scotti R; Tresoldi M; Ciceri F; Landoni G; Zangrillo A; Scarpellini P; Dagna L
    Lancet Rheumatol; 2020 Jun; 2(6):e325-e331. PubMed ID: 32501454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
    Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
    Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.
    Çakmak R; Yüce S; Ay M; Uyar MH; Kılıç Mİ; Bektaş M
    Sci Rep; 2024 May; 14(1):12369. PubMed ID: 38811592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.
    Pasin L; Cavalli G; Navalesi P; Sella N; Landoni G; Yavorovskiy AG; Likhvantsev VV; Zangrillo A; Dagna L; Monti G
    Eur J Intern Med; 2021 Apr; 86():34-40. PubMed ID: 33581979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
    Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G
    Proc Natl Acad Sci U S A; 2020 Aug; 117(32):18951-18953. PubMed ID: 32699149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.
    Kharazmi AB; Moradi O; Haghighi M; Kouchek M; Manafi-Rasi A; Raoufi M; Shoaei SD; Hadavand F; Nabavi M; Miri MM; Salarian S; Shojaei S; Khalili S; Sistanizad M; Sadeghi S; Karagah A; Asgari S; Jaffaraghaei M; Araghi S
    Immun Inflamm Dis; 2022 Feb; 10(2):201-208. PubMed ID: 34762351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
    Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
    Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anakinra for severe forms of COVID-19: a cohort study.
    Huet T; Beaussier H; Voisin O; Jouveshomme S; Dauriat G; Lazareth I; Sacco E; Naccache JM; Bézie Y; Laplanche S; Le Berre A; Le Pavec J; Salmeron S; Emmerich J; Mourad JJ; Chatellier G; Hayem G
    Lancet Rheumatol; 2020 Jul; 2(7):e393-e400. PubMed ID: 32835245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra reduces lung inflammation in experimental acute lung injury.
    Engeroff P; Belbézier A; Monsel A; Klatzmann D
    Immun Inflamm Dis; 2022 Feb; 10(2):123-129. PubMed ID: 34889061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe Covid-19?
    Karakaş Ö; Erden A; Ünlü S; Erol SA; Goncu Ayhan Ş; Özdemir B; Tanacan A; Ozden Tokalioglu E; Ateş İ; Moraloğlu Tekin Ö; Omma A; Şahin D; Küçükşahin O
    Women Health; 2021 Oct; 61(9):872-879. PubMed ID: 34551674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome.
    Steinhardt MJ; Wiebecke S; Weismann D; Frantz S; Tony HP; Klinker H; Schmalzing M
    Scand J Rheumatol; 2020 Sep; 49(5):414-416. PubMed ID: 32914670
    [No Abstract]   [Full Text] [Related]  

  • 19. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
    Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
    Front Immunol; 2020; 11():581338. PubMed ID: 33123167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19.
    Dalekos GN; Stefos A; Georgiadou S; Lygoura V; Michail A; Ntaios G; Samakidou A; Giannoulis G; Gabeta S; Vlychou M; Petinaki E; Leventogiannis K; Giamarellos-Bourboulis EJ; Gatselis NK
    Eur J Intern Med; 2021 Jun; 88():52-62. PubMed ID: 33820686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.